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ABSTRACT
Objective: To study the association between chronic kidney disease (CKD) and hyperprolactinemia.
Methods: The study was conducted in 50 patients with CKD admitted in K.A.P.Viswanatham Government Medical College/M.G.M. Government 
Hospital Tiruchirapalli, between August 2015 and December 2015, who were on maintenance dialysis. Fasting serum prolactin level was measured 
in them to assess the presence of hyperprolactinemia. It was a prospective descriptive cross-sectional study. Quantitative determination of serum 
prolactin was done by fully automated bidirectionally interfaced chemiluminescent immunoassay.
Results: Among the 50 CKD patients, 28 patients had raised serum prolactin levels. According to Statistical analysis of data using t-test, there is a 
significant association between increased serum prolactin levels and presence of CKD.
Conclusion: CKD is associated with increased serum levels of hormone prolactin (hyperprolactinemia).
• Hyperprolactinemia could be detected in 56% of patients with CKD
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INTRODUCTION
Chronic kidney disease (CKD) is characterized by irreversible loss of 
renal function leading to excretory, metabolic, and synthetic failure 
culminating in accumulation of nonprotein nitrogenous substances and 
present with varied clinical manifestations.
Prolactin is a hormone secreted mainly by anterior pituitary gland. In 
addition, prolactin is also secreted by various tissues in the body. Main 
action of prolactin is to control breast development and lactation in 
women. The function of prolactin in men remains to be studied.
CKD is characterized by elevation of serum prolactin levels. Prolactin 
clearance is reduced in CKD, and its production is altered. Prolactin’s 
biological activity is also increased [1].
In male CKD patients, hyperprolactinemia is associated with 
gynecomastia and sexual dysfunction. Hyperprolactinemia is also 
common among female CKD patients. It causes galactorrhea and gonadal 
disturbances with menstrual irregularities, commonly amenorrhea [2].
Several studies conducted recently are showing that prolactin may 
have several biologic actions that participate in the atherosclerotic 
process and leads to insulin resistance. It is also associated with 
endothelial dysfunction. Hyperprolactinemia is found in patients with 
essential hypertension [3], acute phase of coronary syndromes [4], 
during ischemic strokes [5], and transient ischemic attacks and in 
preeclampsia.
Elevated levels of serum prolactin which occurs in CKD may contribute 
to vascular derangements. This might lead to worse cardiovascular 
outcomes among CKD patients. This was undertaken as a prospective 
clinical and biochemical study of serum prolactin levels in CKD patients.
METHODS
The study was conducted in 50 patients with CKD admitted in 
K.A.P.Viswanatham Government Medical College/M.G.M. Government 
Hospital Tiruchirapalli, between August 2015 and December 2015.
The patients who fulfill the criteria for CKD and who were on maintenance 
dialysis were taken into the study. Fasting serum prolactin level was 
measured in them to assess the presence of hyperprolactinemia.
Criteria for CKD
1. Patients with established CKD on maintenance dialysis irrespective 
of etiology
2. Symptoms of uremia for 3 months or more
3. Elevated blood urea, serum creatinine, and decreased creatinine 
clearance
4. Ultrasound evidence for CKD:
a. Bilateral contracted kidney size <8 cm in male and <7cm in 
females
b. Poor corticomedullary differentiation
c. Type II or III renal parenchymal changes
5. The following group of patients was excluded from my study
a. Known patients of hypothyroidism
b. Known patients of chronic liver disease
c. Known patients with seizure disorder
d. Those who are pregnant
e. Patients with prolactinomas, acromegaly, and Cushing’s disease
f. Patients with craniopharyngioma, meningiomas, and sarcoidosis
g. Patients with chest wall lesions, spinal cord lesions
h. Patients with adrenal insufficiency
i. Those patients on following medications:
Phenothiazines, haloperidol, monoamine oxidase inhibitors, tricyclic 
antidepressants, reserpine, methyldopa, metoclopramide, amoxapine, 
cocaine, and verapamil.
Detailed clinical history and examination were undertaken in all 
patients. Height and weight and blood pressure of all patients were 
recorded.
The following investigations were performed in them
Complete blood count, peripheral smear study, erythrocyte 
sedimentation rate, blood urea, serum creatinine, creatinine 
clearance, serum electrolytes, liver function test, lipid profile, urine 
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for albumin, sugar and deposits, and chest X-ray. Electrocardiography, 
ultrasonography abdomen, and fasting serum prolactin level.
After selecting the patients, about 5 ml of blood sample is collected 
in a nonheparinized bottle, and quantitative determination of serum 
prolactin was done by fully automated bidirectionally interfaced 
chemiluminescent immunoassay (CLIA).
The reference range for serum prolactin includes:
Normally menstruating females: 2.8-29.2 ng/ml
• Pregnant women: 9.7-208.5 ng/ml
• Postmenopausal women: 1.8-20.3 ng/ml
• Men: 2.1-17.7 ng/ml.
RESULTS
Among 50 patients, 46 patients were male patients and 4 patients were 
female patients. Among 50 patients with CKD, 29 years to 70 years. 
Among 50 patients with CKD, 7 patients were below 40 years of age, 
18 patients were in the age group of 41-50 years, 17 patients were in 
the age group of 51-60 years, and 8 patients were 61 years and above. 
The duration of CKD in this study varied from 6 months to 8 years 
(Table 5).
The creatinine clearance varied from 4.77 to 46.0. Among the 50 CKD 
patients, 31 had creatinine clearance <15 ml/minutes, 18 patients had 
creatinine clearance 15-30 ml/minutes, and 1 patient had creatinine 
clearance in the range of 30-60 ml/minutes (Table 1).
Among the 50 patients with CKD, blood urea values varied from 
45 mg/dl to 170 mg/dl (Table 2).
Among the CKD patients, serum creatinine values varied between 
1.5 mg/dl and 18.4 mg/dl (Table 3).
In the 50 CKD patients studied all of them were found to be patients of 
systemic hypertension. Among the 50 CKD patients studied 19 patients 
were found to be present with type 2 diabetes mellitus. Among the 
50 CKD patients, dyslipidemias were detected in 16 patients.
Serum prolactin
Serum prolactin level was measured for the 50 patients with CKD using 
fully automated bidirectionally interfaced CLIA. Among the 50 CKD 
patients, 28 patients had raised serum prolactin levels (Table 4).
According to statistical analysis of data using t-test, there is a significant 
association between increased serum prolactin levels and presence of CKD 
(Table 6).
As per the t-test, (Table 7) no significant association could be established 
between raised blood urea levels in patients with CKD and increased 
serum prolactin levels.
According to the results of t-test, (Table 8) no significant association 
could be established between serum creatinine levels in patients with 
CKD and increased serum prolactin levels among them.
As per the statistical analysis using t-test, (Table 9) there was no 
significant association between creatinine clearance in CKD patients 
and increased serum prolactin values in them.
DISCUSSION
In CKD patients, there are alterations in signal feedback mechanisms 
of various hormones in the body. In addition, alteration of hormonal 
production and elimination occurs [6].
Patients with CKD also suffer from various other conditions such as 
protein energy malnutrition, a state of chronic inflammation, multiple 
drug intake, and the presence of metabolic acidosis. Most importantly, 
there is a disturbance in the hypothalamic–pituitary–gonadal axis in 
patients with CKD [7].
One of the major endocrine abnormalities detected in patients with 
CKD is increased serum prolactin levels. Several studies have shown 
that serum prolactin levels remain elevated in patients with CKD. This 
increase occurs in both male and female patients with CKD. This is 








30-60 III 1 2
15-30 IV 18 36
<15 V 31 62
Table 2: Blood urea level
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Item Minimum Maximum Mean Standard 
deviation
Age 29 70 51.46 9.197
Symptom duration ½ 8 4.44 2.052
Urea 45.00 170.00 104.1200 30.30366
Creatinine 1.50 18.4 7.9500 11.79824
Creatinine 
clearance ml/mm
4.77 46.00 14.5244 8.68455
Serum prolactin 
(ng/ml)
4.27 126.59 33.2369 30.67783
Table 6: t‑test, serum prolactin levels (ng/ml) significance of 
association between chronic kidney disease and increased 
serum prolactin levels








Negative (n=22) 5.73 1.830
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thought to be mainly due to reduced clearance by the kidneys. There is an 
alteration in the dopaminergic activity in patients with CKD. This leads 
to increased production of prolactin hormone. This also contributes to 
the increased prolactin levels seen in this group of patients.
A Similar study of evaluating serum prolactin levels in chronic 
renal failure patients, CKD patients on hemodialysis, and transplant 
recipients was conducted by Peces et al. In this study, Peces et al. 
conducted serum prolactin estimation in twelve patients with CKD who 
were on conservative line of treatment and thirty patients with CKD 
who were on hemodialysis, and nineteen patients with CKD who were 
post-transplant recipients with a functioning kidney [7].
At the end of their study, authors have shown that basal levels of serum 
prolactin remain elevated in patients with CKD. This increased serum 
levels of hormone prolactin was demonstrated in both CKD patients 
who were on conservative line of treatment and in CKD patients who 
were on hemodialysis. In their study, the authors also demonstrated 
that the elevated serum prolactin hormone level showed a blunted and 
delayed response to stimulation with TRH. In this study, Peces et al. also 
have shown that Serum prolactin levels remain normal in those CKD 
patients who have received a transplant with functioning kidney. In this 
study, authors have attributed the increased serum prolactin hormone 
levels to decreased renal catabolism and impaired hypothalamo–
pituitary regulation.
A similar study of evaluating hyperprolactinemia and impaired 
pituitary response to suppression and stimulation in patients with 
CKD was conducted by V.S. Lim, S.C. Kathpalia, and L. Frohaman. In this 
study, authors also analyzed the reversibility of the above-mentioned 
abnormalities with renal transplantation. In this study, authors have 
demonstrated increased basal serum prolactin levels in patients with 
CKD. In this study, authors also have demonstrated that prolactin 
hormone showed a lack of responsiveness to suppressive as well as 
stimulatory agents. They attributed this lack of responsive ness to 
pathology at the pituitary either at the level of receptor binding or a 
post-receptor level [8].
Our study is consistent with results of above-mentioned studies in that 
in our study basal serum levels of hormone prolactin remained elevated 
in 56% of CKD patients. There was a statistically significant association 
between increased serum prolactin levels and presence of CKD.
CONCLUSION
• CKD is associated with increased serum levels of hormone prolactin 
(Hyperprolactinemia)
• Hyperprolactinemia could be detected in 56% of patients with CKD.
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Table 7: t‑test, serum prolactin levels (ng/ml), significance of 
association between blood urea levels in chronic kidney disease 
patients and increased serum prolactin levels








Negative (n=22) 95.2273 26.24778
Table 8: t‑test, serum prolactin levels (ng/ml), significance of 
association between serum creatinine levels and increased 
serum prolactin levels








Negative (n=22) 8.6182 17.26468
Table 9: t‑test, serum prolactin (ng/ml), significance of 
association between creatinine clearance and increased serum 











Negative (n=22) 15.9323 7.83744
